Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Around 7% of the Indian population suffers from IBS
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Subscribe To Our Newsletter & Stay Updated